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Material and methods. Patient of 59 years with no history of interest, which is detected in routine screening PSA elevation (8.3ng).
Biopsy: Gleason 3+4 adenocarcinoma (ADC) in 2/3 cylinders right lobe; left lobe (0/3). Prostate volume 25 cm3. Maximum ﬂowme-
try: 22.2ml/s. IPSS: 5. QLQ PR 25: 10 Urinary Incontinence 1, Intestinal 4, Sexual Activity 5, Functionality 8. Negative extension
study. ADC is diagnosed as intermediate risk prostate D’Amico groups say (cT1c). The patient refused surgery for what is referred
to our department to evaluate alternative healing less morbidity. Radiotherapy toyed three options: exclusive Brachytherapy
vs Brachytherapy+CRT vs CRT+short-term androgen deprivation. We opted for exclusive Brachytherapy being shorter treat-
ment which provides reduced toxicity. It makes permanent implant prostate Brachytherapy with I-125 seeds for a dose of PTV
(prostate +margin 5mm) of 145Gy.
Results. At the ﬁrst month post-Brachytherapy PSA levels reached 9.64ng/ml. At 6 months, the PSA down to 3.37 and the score
on the QLQ PR 25 shows an improvement in urinary symptoms and asymptomatic from the standpoint of bowel and sexual. At
12 months is detected PSA nadir (0.9ng/ml).
Conclusion. Intermediate risk patients are candidates mostly combined treatment (CRT+Brachytherapy), but there is a selected
subgroup, in which 100% of experts consulted agree deal with alone Brachytherapy: absence of perineural invasion, cT1c, <30%
cylinders (+) in the biopsy, Gleason 7 (3 + 4) or PSA 10–20ng/ml, obtaining a good control of the diseasewithout providing excessive
toxicity.
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Introduction. The prostate cancer is the most frequent tumor in men; the radiotherapy and brachytherapy are an alternative
treatment highly effective and tolerable. In May of 2011 we have developed LDR brachytherapy technique in our unit, indicated
for low risk prostate cancer patients.
Objectives. To analyze the results in our experience by dosimetric parameters and acute toxicity and comparing with our previous
studies with HDR exclusive brachytherapy.
Material and methods. An observational retrospective study has been realized reviewing the dosimetric and clinics parameters of
44 low risk prostate cancer patients treated with LDR brachytherapy between May of 2011 and December of 2012.
Results. The mean age is 70 years (48–82). The dose administrated was 145Gy I-125. Dosimetric parameters: Prostate (V100: 96.4%,
D90: 114% y V150: 50%), urethra (D1%<160, D10%>150% y D30%>130%) and rectum (D2cc<145Gy y D1cc<160Gy). The treatment
tolerance was acceptable with those results on acute toxicity: dysuria 27.3%, pollakiuria 9%, strangury 25%, urgency 6.8%, acute
urinary retention 2.3%, urinary incontinence 6.8% and proctitis 4.5%. In HDR brachytherapy: The mean age is 71 years (50–79)
who received 34–36Gy in 4 fractions. Dysuria 18%, urgency 6.2%, acute urinary retention 15%, urinary incontinence 6.8% and
proctitis 5%, as acute toxicity.
Conclusions. The LDR brachytherapy is a good option for low risk prostate cancer treatment, based on the dosimetric parameters
and acute toxicity observed, like HDR, highlighting a decreased in acute urinary retention and urinary incontinence. We need
continue monitoring these patients and increased the number of patients included to reach more conclusions.
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Introduction. Patients with intermediate risk prostate neoplasms have been treated using ERBT plus radioactive implants Iodine
125 (LDR) to improve local control.
Material and methods. From 2004 to 2012, 99 ERBT plus LDR implants were performed. Patients (pts) had a median age of 64 (47–76);
Mean PSA is 7.4ng/ml (4–18); Gleason distribution was G6 9 pts (9.1%), G7 85 (85.9%) G8 4 pts (4%) G9 1 pts 1(1%). Tumor stage
distribution was T1 52 pts. (52.5%), T2 45 pts (45.5%), and T3 2 pts (2%). No patients with positive nodes or metastasis were
treated. External radiation therapy was administered on the prostate, seminal vesicles and a margin of safety, at a dose of 45Gy
in 3 cases, 46Gy in 88 cases, 48Gy in 1 case and 50Gy in 7 cases. After external radiotherapy brachytherapy was administered
